Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.

ABSTRACT: Patients with advanced solid malignancies recurrent or resistant to standard therapy have limited treatment options. The role of molecular biomarkers for predicting immune checkpoint blockade (ICB) efficacy are not well characterized in these patients. Tumor mutational profiles of 490 patients with a variety of advanced solid tumors enrolled in a prospective protocol were analyzed to identify prognostic and predictive biomarkers. ICB therapy was defined as treatment with any CTLA-4, PD-1, and/or PD-L1 monoclonal antibody. ICB treatment was associated with significantly improved overall survival compared to non-ICB therapy. Multivariate regression analysis including the two variables of tumor mutation burden (TMB) and ICB, and their interaction term, showed favorable survival associa

SUBMITTER: Yang RK 

PROVIDER: S-EPMC7021232 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature